CA3162280A1 - 4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitors - Google Patents
4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitorsInfo
- Publication number
- CA3162280A1 CA3162280A1 CA3162280A CA3162280A CA3162280A1 CA 3162280 A1 CA3162280 A1 CA 3162280A1 CA 3162280 A CA3162280 A CA 3162280A CA 3162280 A CA3162280 A CA 3162280A CA 3162280 A1 CA3162280 A1 CA 3162280A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- chloro
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946100P | 2019-12-10 | 2019-12-10 | |
| US62/946,100 | 2019-12-10 | ||
| PCT/US2020/064191 WO2021119242A1 (en) | 2019-12-10 | 2020-12-10 | Replication protein a (rpa)-dna interaction inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3162280A1 true CA3162280A1 (en) | 2021-06-17 |
Family
ID=76330773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3162280A Pending CA3162280A1 (en) | 2019-12-10 | 2020-12-10 | 4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12486246B2 (https=) |
| EP (1) | EP4073055A4 (https=) |
| JP (1) | JP7677646B2 (https=) |
| BR (1) | BR112022011372A2 (https=) |
| CA (1) | CA3162280A1 (https=) |
| WO (1) | WO2021119242A1 (https=) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| EP2402323A3 (en) * | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| EP1905762A1 (en) | 2005-05-30 | 2008-04-02 | Genecare Research Institute Co., Ltd | Pyrazolone derivative |
| US20100055116A1 (en) | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
| WO2008045663A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| MY150697A (en) | 2007-04-10 | 2014-02-28 | Exelixis Inc | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha |
| WO2008148747A2 (en) | 2007-06-08 | 2008-12-11 | University Of Copenhagen | Pdz domain modulators |
| US8476458B2 (en) | 2007-06-21 | 2013-07-02 | The Wistar Institute | Methods and compositions for modulating P300/CBP activity |
| HRP20161004T1 (hr) | 2007-09-27 | 2016-10-21 | Dow Agrosciences Llc | Tehnološki konstruirani proteini cinkovi prsti koji imaju kao cilj gene za sintazu 5-enolpiruvilshikimat-3-fosfata |
| WO2009145829A1 (en) | 2008-04-01 | 2009-12-03 | University Of Massachusetts | Type iii secretion inhibitors, analogs and uses thereof |
| WO2009146179A1 (en) | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CA2825680C (en) | 2010-02-05 | 2019-12-03 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
| WO2012037573A1 (en) | 2010-09-17 | 2012-03-22 | Indiana University Research And Technology Corporation | Small molecule inhibitors of replication protein a that also act synergistically with cisplatin |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| JP6482546B2 (ja) | 2013-07-19 | 2019-03-13 | ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニーＬａｒｉｘ Ｂｉｏｓｃｉｅｎｃｅ， Ｌｌｃ | 二重対立遺伝子ノックアウトを生成するための方法および組成物 |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| ITMI20131410A1 (it) | 2013-08-26 | 2015-02-27 | Univ Degli Studi Modena E Reggio Emilia | Composti e composizioni per l'uso nella inibizione dell' interazione lbc-rhoa |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| WO2016077752A2 (en) * | 2014-11-13 | 2016-05-19 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
| WO2017205503A1 (en) | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
| CA3075734A1 (en) | 2017-09-19 | 2019-03-28 | Indiana University Research And Technology Corporation | Xpa inhibitor compounds and their use |
-
2020
- 2020-12-10 BR BR112022011372A patent/BR112022011372A2/pt unknown
- 2020-12-10 CA CA3162280A patent/CA3162280A1/en active Pending
- 2020-12-10 US US17/782,876 patent/US12486246B2/en active Active
- 2020-12-10 EP EP20897908.8A patent/EP4073055A4/en active Pending
- 2020-12-10 JP JP2022535116A patent/JP7677646B2/ja active Active
- 2020-12-10 WO PCT/US2020/064191 patent/WO2021119242A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US12486246B2 (en) | 2025-12-02 |
| JP7677646B2 (ja) | 2025-05-15 |
| EP4073055A1 (en) | 2022-10-19 |
| BR112022011372A2 (pt) | 2022-08-23 |
| US20230056729A1 (en) | 2023-02-23 |
| WO2021119242A1 (en) | 2021-06-17 |
| JP2023505690A (ja) | 2023-02-10 |
| EP4073055A4 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2253625B1 (en) | Pyridazinones, the preparation and the use thereof | |
| JP4405602B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
| EP3438094A1 (en) | Selective c-kit kinase inhibitor | |
| EP3927683A1 (en) | Solid forms of fxr agonists | |
| WO2017101803A1 (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
| KR20170053686A (ko) | Raf 키나제 억제제로서의 화합물 및 조성물 | |
| CA3097925A1 (en) | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor | |
| JP6821680B2 (ja) | １，３，４−チアジアゾール化合物およびがんの治療におけるその使用 | |
| JP2016503003A (ja) | ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン | |
| WO2012073184A1 (en) | Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases | |
| JP2023529570A (ja) | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン | |
| JP2013515766A (ja) | イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物 | |
| Yuan et al. | Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy | |
| EP3440070A2 (en) | Mdr-reversing 8-hydroxy-quinoline derivatives | |
| CN109476649B (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| CA2824028A1 (en) | Novel ureas for the treatment and prevention of cancer | |
| AU2018321287A1 (en) | Azole analogues and methods of use thereof | |
| US12486246B2 (en) | Replication protein A (RPA)-DNA interaction inhibitors | |
| EP3242881B1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
| WO2017181974A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| CN107459491A (zh) | 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途 | |
| CN107513040A (zh) | 取代苯并嘧啶类化合物的制备及分子靶向肿瘤治疗药物的应用 | |
| EP3049386B1 (en) | Compounds useful in the treatment of neoplastic diseases | |
| CN107501283A (zh) | 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用 | |
| WO2025240834A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220915 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |